Bempedoic acid 180 mg tablet
DrugPatients take bempedoic acid 180 mg tablet orally once daily
Other names: ETC-1002
NCT Number: NCT02993406
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Phase 3
Bahía Blanca, Buenos Aires, Argentina
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Please note that participants currently tolerating very low dose statin therapy (an average daily dose of rosuvastatin <5 mg, atorvastatin <10 mg, simvastatin <10 mg, lovastatin <20 mg, pravastatin <40 mg, fluvastatin <40 mg, or pitavastatin <2 mg) are considered to be intolerant to that low dose statin. Patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least 4 weeks prior to screening) and well tolerated.
Exclusion criteria
Patients take bempedoic acid 180 mg tablet orally once daily
Other names: ETC-1002
Patients take matching placebo tablet orally once daily
Other names: placebo comparator
Time frame: Up to 68 months
The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.
Time frame: Up to 68 months
The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
Time frame: Up to 68 months
Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.
Time frame: Up to 68 months
Number of participants with time to first occurrence of coronary revascularization are presented.
Time frame: Up to 68 months
Number of participants with time to first occurrence of fatal and non-fatal stroke.
Time frame: Up to 68 months
Number of participants with time to cardiovascular death are presented.
Time frame: Up to 68 months
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
Esperion Therapeutics, Inc.
Industry
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
Acronym: CLEAR Outcomes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT02439775
Cardiovascular Diseases, Hypertension
Huntsville, Alabama, United States
View Trial DetailsNCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial Details